TNF Blockers News and Research

RSS

Extracorporeal photopheresis may be effective in treating Crohn's disease

Results from an international multi-center Phase II clinical trial suggest that extracorporeal photopheresis (ECP) may be effective in treating patients with clinically active (OR symptomatic) Crohn?s disease who cannot tolerate or are refractory to immunosuppressants and/or anti-TNF agents.

28 May 2007

Abbott seeks U.S. and E.U. approvals for Humira as a treatment for juvenile rheumatoid arthritis

Abbott has announced it has simultaneously submitted a supplemental Biologics License Application (sBLA) with the U.S. Food and Drug Administration (FDA) and a Type II Variation to the European Medicines Agency (EMEA) seeking approval to market HUMIRA (adalimumab) as a treatment for juvenile rheumatoid arthritis (JRA) in the U.S. and juvenile idiopathic arthritis (JIA) in the European Union (EU).

9 May 2007

Heart-assist devices may help some end-stage heart failure patients avoid transplant

Implanted pumps improved heart function enough in a small percentage of patients awaiting a heart transplant that they were able to leave the hospital without a pump and without a new heart, according to a study in Circulation: Journal of the American Heart Association.

8 May 2007

Facts about rheumatoid arthritis and aging

For the better part of three decades, Sherrie Kossoudji has endeavored each day to manage the inflammation, chronic pain, tight joints and other types of physical strife caused by rheumatoid arthritis.

8 May 2007

Infliximab fails to improve chronic obstructive pulmonary disease symptoms

A promising anti-inflammatory drug failed to improve symptoms of moderate to severe chronic obstructive pulmonary disease, or COPD, in a large, multi-center trial.

2 May 2007

Genetic risk for early death in rheumatoid arthritis

A chronic autoimmune disease, rheumatoid arthritis (RA) is marked by inflammation that takes a progressive toll on not only the joints, but also various organs and the whole body.

30 Apr 2007

Professor Marc Feldmann wins top lifetime achievement award

The academic who developed a treatment for autoimmune diseases that has helped millions of patients around the world last night received a prestigious lifetime achievement award at this year's European Inventor of the Year awards.

24 Apr 2007

Green tea may help protect against Sjogren's syndrome

They found significantly less salivary gland damage in a group treated with green tea extract, suggesting a reduction of the Sjogren's symptom commonly referred to as dry mouth. Dry mouth can also be caused by certain drugs, radiation and other diseases.

20 Apr 2007

Abbott opens biotech facility in Puerto Rico

"This new facility is a key milestone for Abbott as we move to focus our resources and future growth on biologic and potent-drug manufacturing," said Lawrence Kraus, vice president of manufacturing, global pharmaceutical operations, Abbott.

11 Apr 2007

Researchers show blood-brain barrier damage could affect multiple sclerosis severity

Immunology researchers at the Kimmel Cancer Center at Jefferson studying a multiple sclerosis (MS)-like disease in mice have shown that the amount of "damage" to the central nervous system's protective blood-brain barrier, in essence, opening it, almost always correlates to the severity of the disease.

7 Apr 2007

Efficacy of Guanilib confirmed for inflammatory bowel disease

Callisto Pharmaceuticals has announced additional data confirming efficacy of Guanilib, a first-in-class compound currently being developed for the treatment of inflammatory bowel disease (IBD), in two different standard animal models of experimental colitis.

7 Apr 2007

We need to balance out our intake of omega-6 and omega-3 fatty acids

A new study suggests that people whose diets contain dramatically more of one kind of polyunsaturated fatty acid than another may be at greater risk for both clinical depression and certain inflammatory diseases.

3 Apr 2007

Decoy receptor 3 expressed in rheumatic synovial fibroblasts protects the cells against Fas-induced apoptosis

A complex autoimmune disease, rheumatoid arthritis (RA) is characterized by chronic inflammation and progressive joint damage. This process begins with hyperplasia, or excessive increase in size and thickness, of synovial tissue. Along with provoking cartilage and bone destruction, this abnormal tissue growth is resistant to apoptosis, the natural cell death vital to the generation of healthy new cells.

30 Mar 2007

FDA approves Humira (adalimumab) for Crohn's disease

The U.S. Food and Drug Administration (FDA) today approved Humira (adalimumab) to treat adult patients with moderately to severely active Crohn's disease, a chronic inflammatory disease of the intestines, which affects an estimated one million Americans.

27 Feb 2007

Arthritis drugs not as risky as first thought

Researchers now say that two biotech drugs used to treat rheumatoid arthritis, Humira (Abbott Laboratories) and Remicade (Johnson & Johnson), may not raise the risk of cancer and infections as much as was initially feared.

8 Nov 2006

Topical treatment for psoriasis, eliminates need for injections

Apollo Life Sciences, a Sydney-based biotechnology company, has announced that its topical psoriasis treatment has outperformed current market-leading drugs in preclinical studies.

17 Oct 2006

Study reveals white blood cells can both hurt and help transplanted kidneys

In an example of biological irony, the same white blood cell chemistry known to damage kidneys used for transplants may also help prevent such damage, according to a federally funded study in genetically engineered mice at Johns Hopkins.

21 Sep 2006

Tumor necrosis factor A antagonist use and cancer in patients with rheumatoid arthritis

Patients with rheumatoid arthritis (RA), an autoimmune, inflammatory disease marked by progressive joint and organ damage, face a high risk of developing cancer.

31 Aug 2006

NICE backs use of Enbrel and Raptiva to treat severe psoriasis

NICE has today issued guidance for the use of the targeted biological therapies, Enbrel (etanercept) and Raptiva (efalizumab), to treat adult patients with severe plaque psoriasis.

26 Jul 2006

Rituximab shown to significantly inhibit structural damage of joints caused by rheumatoid arthritis

New data presented at the EULAR meeting (European League Against Rheumatism) show for the first time that MabThera (rituximab), a unique B cell targeted therapy, is able to significantly inhibit structural damage of joints caused by rheumatoid arthritis (RA).

27 Jun 2006